A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Arbaclofen placarbil (Primary)
  • Indications Alcohol-related disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Indivior; Reckitt Benckiser
  • Most Recent Events

    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 03 May 2016 The results of this trial are expected in Q3 2016, according to an INDIVIOR media release.
    • 28 Dec 2015 Planned End Date changed from 1 Apr 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top